

# Chapter 216

## Topical Corticosteroids

Isabel C. Valencia & Francisco A. Kerdel

### REFERENCES

1. Brazzini B, Pimpinelli N: New and established corticosteroids in dermatology. *Am J Clin Dermatol* 3:47, 2002
2. Lewis-Tuffin LJ et al: Human corticoid receptor  $\beta$  binds RU-486 and is transcriptionally active. *Mol Cell Biol* 27:2266, 2007
3. Haag PM et al: Increased expression of glucocorticoid receptor  $\beta$  in lymphocytes of patients with severe atopic dermatitis unresponsive to topical corticosteroid. *Br J Dermatol* 162:318, 2010
4. De Bosscher K, Vanden Berghe W, Haegeman G: Mechanism of anti-inflammatory action of immunosuppression by glucocorticoids: Negative interference of activated glucocorticoid receptor with transcription factors. *J Neuroimmunol* 109:16, 2000
5. Biola A, Ballardry M: Mode of action of glucocorticoids. *Presse Med* 29:215, 2000
6. Blackwell GJ et al: Macrocortin: a polypeptide causing the antiphospholipase effect of glucocorticosteroids. *Nature* 287:147, 1980
7. Hirata F et al: A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticosteroids. *Proc Natl Acad Sci USA* 77:2533, 1980
8. Kragballe K: Topical corticosteroids: Mechanisms of action. *Acta Derm Venereol* 69:7, 1989
9. Katchman SD: A transgenic mouse model provides a novel biological assay of topical corticosteroid potency. *Arch Dermatol* 131:1274, 1995
10. Prillo JE, Fauci AS: Mechanisms of glucocorticoid action on immune processes. *Ann Rev Pharmacol Toxicol* 19:179, 1979
11. Vernon-Roberts B: The effects of steroid hormones on macrophage activity. *Tnt Rev Cytol* 25:131, 1969
12. Thompson J, van Furth R: The effect of glucocorticosteroids on the kinetics of mononuclear phagocytes. *J Exp Med* 131:429, 1970
13. Lavker RM et al: Cutaneous mast cell depletion results from topical corticosteroid usage. *J Immunol* 135:2368, 1985
14. Norris DA et al: The effect of epicutaneous glucocorticosteroids on human monocyte and neutrophil migration in vivo. *J Invest Dermatol* 78:386, 1982
15. Furue M, Katz SI: Direct effects of corticosteroids on epidermal Langerhans cells. *J Invest Dermatol* 92:342, 1989
16. Ashwell JD, Lu FW, Vacchio MS: Glucocorticosteroids in T cell development and function. *Annu Rev Immunol* 18:309, 2000
17. Guyre PM et al: Glucocorticoid effects on the production and actions of immune cytokines. *J Steroid Biochem Mol Biol* 30:89, 1988 [PMID: 2968487]
18. Almawi WY et al: Partial mediation of glucocorticoid antiproliferative effects by lipocortins. *J Immunol* 157:5231, 1996
19. Smith EW: Do we need new and different glucocorticoids? *Curr Probl Dermatol* 21:1, 1993
20. Altura BM: Role of glucocorticosteroids in local regulation of blood flow. *Am J Physiol* 211:1393, 1966
21. Juhlin L, Michaelsson G: Cutaneous vascular reactions to prostaglandins in healthy subjects and in patients with urticaria and atopic dermatitis. *Acta Derm Venereol* 49:251, 1969
22. Brattsand R: Influence of 16, 17-acetyl substitution and steroid nucleus fluorination on the topical to systemic activity ratio of corticosteroids. *J Steroid Biochem* 16:779, 1982
23. Korting HC et al: Topical glucocorticoids with improved benefit-risk ratio: Do they exist? *J Am Acad Dermatol* 27:87, 1992
24. Roeder A et al: Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. *Skin Pharmacol Physiol* 18:3, 2005
25. Mori M, Pimpinelli N, Giannotti B: Topical corticosteroids and unwanted local effects: Improving the benefit/risk ration. *Drug Saf* 10:406, 1994
26. Maibach HI, Wester RC: Issues in measuring percutaneous absorption of topical corticosteroids. *Int J Dermatol* 31(Suppl. 1):21, 1992
27. Praiser D: Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: Focus on percutaneous absorption. *Am J Therap* 16:264, 2009

28. McClain RW, Yentzer BA, Feldman SR: Comparison of skin concentrations following topical versus oral corticosteroid treatment: Reconsidering the treatment of common inflammatory dermatoses. *J Drugs in Dermatol* **8**(12):1076, 2009
29. Jarrat MT et al: Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. *Cutis* **78**:348, 2006
30. Warino L, Balkrishnan R, Feldman SR. CLobetasol propionate for psoriasis: are ointments really more potent? *J Drugs Dermatol* **5**:527-532, 2006
31. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: A review of newer formulations. *Am J Clin Dermatol* **10**(6):397, 2009
32. Tadicherla S et al: Topical corticosteroids in dermatology. *J Drugs in Dermatol* **8**(12):1093, 2009
33. Bingham LG, Noble JW, Davis MDP: Wet dressings use with topical corticosteroids for pruritic dermatoses: A retrospective study. *J Am Acad Dermatol* **60**:792, 2009
34. West DP et al: Pharmacology and toxicology of infant skin. *J Invest Dermatol* **76**:147, 1981
35. Holbrook K, Sybert V: Basic science. In: *Pediatric Dermatology*, edited by L Schachner, R Hansen. New York, Churchill Livingstone, 1995, p. 17
36. Cook LJ et al: Iatrogenic hyperadrenocorticism during topical steroid therapy: Assessment of systemic effects by metabolic criteria. *J Am Acad Dermatol* **6**:1054, 1982
37. Charman C: Clinical evidence: Atopic eczema. *BMJ* **318**:1600, 1999
38. Zuberbier T et al: Patient perspectives on the management of atopic dermatitis. *J Allergy Clin Immunol* **118**:226, 2006
39. Charman CR, Morris AD, Williams HC: Topical corticosteroid phobia in patients with atopic eczema. *Br J Dermatol* **142**:931, 2000
40. Del Rosso J, Friedlander SF: Corticosteroids: Options in the era of steroid-sparing therapy. *J Am Acad Dermatol* **53**:S50, 2005
41. Garzon MC et al: Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. *J Am Acad Dermatol* **52**:281, 2005
42. Hasan Q et al: Steroid therapy of proliferating hemangioma: Histochemical and molecular changes. *Pediatrics* **105**:117, 2000
43. Chi C-C et al: Systematic review of the safety of topical corticosteroids in pregnancy. *J Am Acad Derm* **62**(4):694-705, 2010
44. Lagos BR, Maibach HI: Frequency of application of topical corticosteroids: An overview. *Br J Dermatol* **139**:763, 1998
45. Singh G et al: Tachyphylaxis to topical steroids measured by histamine-induced wheal suppression. *Int J Dermatol* **25**:324, 1986
46. Hughes J, Rustin M: Corticosteroids. *Clin Dermatol* **15**:715, 1997
47. Gianotti B, Pimpinelli N: Topical corticosteroids: Which drug and when? *Drugs* **44**:65, 1992
48. Gilbertson EO et al: Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations. *J Am Acad Dermatol* **38**:318, 1998
49. Hengge UR et al: Adverse effects of topical glucocorticosteroids. *J Am Acad Dermatol* **54**:1, 2006
50. Miller JA, Munro DD: Topical corticosteroids: Clinical pharmacology and therapeutic use. *Drugs* **19**:119, 1980
51. Fusaro RM, Kingsley DN: Topical glucocorticoids: How they are used and misused. *Postgrad Med* **79**:283, 1986
52. Schoepe S et al: Glucocorticoid therapy-induced skin atrophy. *Exp Dermatol* **15**:406, 2006
53. Nuutinen P et al: Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin. *Br J Dermatol* **148**:39-45, 2003
54. Oikarinen A et al: The molecular basis of glucocorticoid-induced skin atrophy topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. *Br J Dermatol* **139**:1106, 1998
55. Sarnstrand B, Brattsand R, Malmstrom A: Effect of glucocorticoids on glycosaminoglycan metabolism in cultured human skin fibroblasts. *J Invest Dermatol* **79**:412, 1982
56. Gebhardt C et al: Dermal hyaluronan is rapidly reduced by topical treatment with glucocorticoids. *J Invest Dermatol* **130**:141, 2010
57. Aucott JN: Glucocorticoids and infection. *Endocrinol Metab Clin North Am* **23**:655, 1994
58. Mimesh S, Pratt M: Allergic contact dermatitis from corticosteroids: Reproducibility of patch testing and correlation with intradermal testing. *Dermatitis* **17**(3):137, 2006
59. Lutz ME, el-Azhary RA: Allergic contact dermatitis due to topical application of corticosteroids: Review and clinical implications. *Mayo Clin Proc* **72**:1141, 1997

60. Issakson M et al: Patch testing with corticosteroid mixes in Europe. A multicentre study of the EECDRG. *Contact Dermatitis* **42**:27, 2000
61. Davis MD, el Azhary RA, Farmer SA: Results of patch testing to a corticosteroid series: A retrospective review of 1188 patients during 6 years at Mayo Clinic. *J Am Acad Dermatol* **56**:921, 2009
62. Marlene I, Magnus B: Contact allergen of the year: Corticosteroids. *Dermatitis* **16**:3, 2005
63. Sharon E. Jacob, Tace Steele: Corticosteroid classes: A quick reference guide including patch test substances and cross-reactivity. *J Am Acad Dermatol* **54**(4):723, 2006
64. Coloe J, Zirwas MJ: Allergens in corticosteroid vehicles. *Dermatitis* **19**(1):38, 2008
65. Cubey R: Glaucoma following application of corticosteroid to the skin of the eyelids. *Br J Dermatol* **95**:207, 1976
66. Zuger C, Saunders D, Levit F: Glaucoma from topically applied steroids. *Arch Dermatol* **112**:1236, 1976
67. Neilsen NV, Sorenson PN: Glaucoma induced by application of corticosteroids to the periorbital region. *Arch Dermatol* **114**:953, 1978
68. Aggarwal RK et al: Extensive visual loss with topical facial steroids. *Eye* **6**:664, 1993
69. Halverstam CP, Vachharajani A, Mallory SB: Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome. *Pediatr Dermatol* **24**:42, 2007
70. Pike MG et al: Growth in atopic eczema: A controlled study by questionnaire. *Arch Dis Child* **64**:1566, 1989
71. Kristmundsdottir F, David TJ: Growth impairment in children with atopic eczema. *J R Soc Med* **80**:9, 1987
72. Patel L et al: Adult height in individuals with childhood onset atopic dermatitis. *Arch Dis Child* **76**:505, 1997
73. Thomas MW, Panter AT, Morrell DS: Corticosteroids effects on the height of atopic dermatitis patients: A controlled questionnaire study. *Pediatr Dermatol* **26**(5):524, 2009
74. Kane D, Barnes L, Fitzgerald O: Topical corticosteroid treatment: Systemic side effects. *Br J Dermatol* **149**:417, 2003
75. El Magharauoi A et al: Femoral head osteonecrosis after topical corticosteroid therapy. *Clin Exp Rheumatol* **19**(2): 233, 2001
76. McLean CJ, Lobo RF, Brazier DJ: Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. *Lancet* **345**(8945):330, 1995

